Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 + adebrelimab vs investigator's choice in adjuvant treatment of residual triple-negative breast cancer
CTR20262490Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab rezetecan in triple-negative breast cancer (TNBC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Sep 2026; status: active.
02
Drugs
trastuzumab rezetecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20262490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262490.